CAR-T cell therapy for B-cell acute lymphoblastic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 5 and 50 years old.
- You must have B-cell ALL that is CD19-positive, meaning the cancer cells have a specific protein on their surface.
- Your leukemia must be in relapse or resistant to standard treatments, or you must not be able to have a stem cell transplant.
- You need to have adequate organ function (kidney, liver, heart, lungs) and be in generally good health.
- You cannot have had prior CAR-T therapy or certain other treatments recently.
- You must be willing to follow the study schedule and long-term follow-up, including 15 years of monitoring.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a patient's own T cells, modified to target a protein called CD19 on cancer cells, to treat B-cell cancers that have come back or not responded to standard treatments. It is for people aged 14 to 70 with certain types of leukemia or lymphoma.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
This trial tests a new CAR-T cell treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. It aims to see if these immune cells can safely and effectively fight the cancer.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests an engineered immune-cell treatment (GC019F CAR-T) for adults with B-cell ALL that has come back or did not respond to prior therapy. If it works, it may help your immune system attack leukemia cells by targeting CD19.
Hear when a new Relapsed Acute Lymphoblastic Leukemia (ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.